ECSP066681A - Formas sólidas de anticuerpos anti-egfr - Google Patents

Formas sólidas de anticuerpos anti-egfr

Info

Publication number
ECSP066681A
ECSP066681A EC2006006681A ECSP066681A ECSP066681A EC SP066681 A ECSP066681 A EC SP066681A EC 2006006681 A EC2006006681 A EC 2006006681A EC SP066681 A ECSP066681 A EC SP066681A EC SP066681 A ECSP066681 A EC SP066681A
Authority
EC
Ecuador
Prior art keywords
solid forms
antibodies
mab
aqueous medium
egfr antibodies
Prior art date
Application number
EC2006006681A
Other languages
English (en)
Inventor
Hanns-Christian Mahler
Susanne Matheus
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34625406&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066681(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP066681A publication Critical patent/ECSP066681A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Metallurgy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere a formas sólidas de anticuerpos contra el receptor EGF, en particular a precipitados y cristales de anticuerpos monoclonales contra el receptor EGF, con preferencia particular de Mab C225 (cetuximab) y Mab h425 (EMD 72000), que dan como resultado proteínas de anticuerpo biológicamente activas por disolución o la suspensión en medio acuoso, que se pueden obtener por precipitación del anticuerpo y/o una de sus variantes y/o fragmentos disueltos o suspendidos en medio acuoso por medio de un reactivo de precipitación. La invención también se refiere a preparaciones farmacéuticas que comprenden al menos una forma sólida de los anticuerpos antes mencionados en forma de precipitado no cristalino, precipitado cristalino o en forma soluble o suspendida, y opcionalmente excipientes y/o coadyuvantes y/u otros ingredientes activos farmacéuticos, y a un procedimiento para preparar formas sólidas de anticuerpos anti-EGFR de acuerdo con la invención.
EC2006006681A 2003-11-29 2006-06-28 Formas sólidas de anticuerpos anti-egfr ECSP066681A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10355904A DE10355904A1 (de) 2003-11-29 2003-11-29 Feste Formen von anti-EGFR-Antikörpern

Publications (1)

Publication Number Publication Date
ECSP066681A true ECSP066681A (es) 2006-10-25

Family

ID=34625406

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006681A ECSP066681A (es) 2003-11-29 2006-06-28 Formas sólidas de anticuerpos anti-egfr

Country Status (21)

Country Link
US (1) US7960516B2 (es)
EP (2) EP1974723A3 (es)
KR (2) KR20120093406A (es)
CN (1) CN1886118A (es)
AR (1) AR046677A1 (es)
AU (1) AU2004292742B9 (es)
BR (1) BRPI0416968A (es)
CA (1) CA2547446C (es)
CO (1) CO5690537A2 (es)
DE (1) DE10355904A1 (es)
EC (1) ECSP066681A (es)
IL (1) IL175935A (es)
MX (1) MXPA06005968A (es)
MY (1) MY148228A (es)
NZ (1) NZ548210A (es)
PE (1) PE20050667A1 (es)
RU (1) RU2397755C2 (es)
TW (1) TWI350291B (es)
UA (1) UA84893C2 (es)
WO (1) WO2005051355A1 (es)
ZA (1) ZA200605348B (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
HK1047236A1 (zh) * 1999-05-14 2003-02-14 Imclone Llc 用表皮生长因子受体拮抗剂治疗难治的人肿瘤
JP2004527456A (ja) * 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
JP2006506317A (ja) 2002-01-11 2006-02-23 バイオマリン ファーマシューティカル インコーポレイテッド 治療用リソソーム酵素の送達のための酵素送達系としてのｐ９７の使用
EP1622941A2 (en) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
PT1735348E (pt) * 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
WO2005112893A1 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
JP2007537288A (ja) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド オリゴヌクレオチド含有マイクロスフェア、１型糖尿病を処置する医薬の製造のための、その使用
EP2335689A1 (en) 2004-05-12 2011-06-22 Baxter International Inc. Method of manufacturing nucleic acid micropheres
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
JP5118139B2 (ja) 2006-08-04 2013-01-16 バクスター・インターナショナル・インコーポレイテッド 新規発症自己免疫性糖尿病を予防および／または逆転させるためのマイクロスフィアに基づく組成物
NZ576133A (en) * 2006-10-27 2012-10-26 Abbott Biotech Ltd Crystalline anti-htnfalpha antibodies
JP5744513B2 (ja) 2007-04-17 2015-07-08 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 肺送達のための核酸微小粒子
WO2009020654A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
WO2009051726A1 (en) * 2007-10-15 2009-04-23 Biogen Idec Ma Inc. Methods of manufacturing a biologic using a stable storage intermediate
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US10143652B2 (en) * 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
CN102153648B (zh) * 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗egfr人源化抗体l4-h3及其编码基因与应用
AU2012278944B2 (en) 2011-07-05 2015-09-17 Bioasis Technologies Inc. p97-antibody conjugates and methods of use
EP2739649B1 (en) 2011-08-05 2017-09-27 Bioasis Technologies Inc. P97 fragments with transfer activity
CN104662150B (zh) 2012-07-31 2018-07-10 比奥阿赛斯技术有限公司 脱磷酸化的溶酶体贮积症蛋白及其使用方法
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
JP6586412B2 (ja) 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７のフラグメントおよびその使用
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
ES2764973T3 (es) 2014-02-03 2020-06-05 Bioasis Technologies Inc Proteínas de fusión de P97
ES2762672T3 (es) 2014-02-19 2020-05-25 Bioasis Technologies Inc Proteínas de fusión de P97-IDS
WO2015168521A2 (en) 2014-05-01 2015-11-05 Bioasis Technologies, Inc. P97-polynucleotide conjugates
AU2015355965B2 (en) * 2014-12-04 2019-07-04 Delta-Fly Pharma, Inc. Novel PEG derivative
KR20170117473A (ko) * 2015-02-15 2017-10-23 지앙수 헨그루이 메디슨 컴퍼니 리미티드 리간드-세포독성 약물 접합체, 이의 제조 방법 및 이의 적용
CN106999606B (zh) * 2015-02-17 2020-06-19 上海美雅珂生物技术有限责任公司 抗体药物偶联物
AR103726A1 (es) * 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
TW201709932A (zh) * 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
CN107735105B (zh) * 2015-06-30 2022-09-16 西雅图基因公司 抗ntb-a抗体和相关组合物以及方法
CN105810072A (zh) * 2016-03-25 2016-07-27 淮海工学院 一种蛋白质结晶的教学试剂盒及其方法
CN116333130A (zh) 2016-05-24 2023-06-27 英斯梅德股份有限公司 抗体及其制备方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CA3103327A1 (en) * 2018-06-18 2019-12-26 Bayer Aktiengesellschaft Binder/active agent conjugates directed against cxcr5, having enzymatically cleavable linkers and improved activity profile
KR20210044251A (ko) 2018-08-13 2021-04-22 베이징 페르칸스 온콜로지 컴퍼니 리미티드 암 치료용 바이오마커
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CN113015748B (zh) 2018-10-31 2025-12-12 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
EP3986479A1 (en) * 2019-06-21 2022-04-27 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
US12485181B2 (en) * 2019-06-28 2025-12-02 Serina Therapeutics (Al), Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties
WO2022011458A1 (en) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
CN119792564A (zh) * 2020-08-13 2025-04-11 正大天晴药业集团股份有限公司 抗体药物偶联物
CN114099422A (zh) * 2020-08-25 2022-03-01 泰州迈博太科药业有限公司 一种重组抗egfr单抗前体的制剂
AU2020479745A1 (en) * 2020-12-04 2023-07-20 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
CN115073437B (zh) * 2021-03-11 2023-07-18 北京师范大学 基于二氰基吡喃的大环多胺[12]aneN3化合物及其制备方法与用途
CN114652826B (zh) * 2022-01-24 2022-10-14 景泽生物医药(合肥)有限公司 抗egfr抗体的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
KR100240308B1 (ko) * 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
WO1993000807A1 (en) 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
ATE188874T1 (de) 1992-08-18 2000-02-15 Centro Inmunologia Molecular Monoklonale antikörper gegen den epidermalen wachstumsfaktorrezeptor, zellen und verfahren zur ihrer herstellung und sie erhaltende zusammensetzungen
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0831880A4 (en) * 1995-06-07 2004-12-01 Imclone Systems Inc ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
JP4731793B2 (ja) * 2000-12-28 2011-07-27 アルセア テクノロジーズ インコーポレイテッド 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
EP1389090A2 (en) * 2001-04-26 2004-02-18 Board of Regents, The University of Texas System Diagnostic imaging compositions, their methods of synthesis and use
DE10133394A1 (de) 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
US20110142822A1 (en) * 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof

Also Published As

Publication number Publication date
CA2547446C (en) 2013-05-14
CO5690537A2 (es) 2006-10-31
TWI350291B (en) 2011-10-11
AU2004292742B2 (en) 2011-08-25
NZ548210A (en) 2010-10-29
KR20120093406A (ko) 2012-08-22
WO2005051355A1 (de) 2005-06-09
KR20060111539A (ko) 2006-10-27
ZA200605348B (en) 2007-04-25
RU2006123005A (ru) 2008-01-20
BRPI0416968A (pt) 2007-02-21
EP1974723A2 (de) 2008-10-01
MY148228A (en) 2013-03-29
CN1886118A (zh) 2006-12-27
US20070122411A1 (en) 2007-05-31
AR046677A1 (es) 2005-12-14
DE10355904A1 (de) 2005-06-30
IL175935A0 (en) 2006-10-05
AU2004292742A1 (en) 2005-06-09
US7960516B2 (en) 2011-06-14
EP1686961A1 (de) 2006-08-09
IL175935A (en) 2013-10-31
TW200530268A (en) 2005-09-16
RU2397755C2 (ru) 2010-08-27
UA84893C2 (en) 2008-12-10
AU2004292742B9 (en) 2011-11-24
PE20050667A1 (es) 2005-09-27
MXPA06005968A (es) 2006-07-06
EP1974723A3 (de) 2010-06-09
CA2547446A1 (en) 2005-06-09

Similar Documents

Publication Publication Date Title
ECSP066681A (es) Formas sólidas de anticuerpos anti-egfr
ZA202205141B (en) Formulations of human anti-rankl antibodies, and methods of using the same
JP6518199B2 (ja) Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
BRPI1015917A2 (pt) antígenos de rsv recombinantes.
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
PE20071055A1 (es) Anticuerpos anti mn
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
NZ719036A (en) Anti-pdl1 antibody formulations
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
UA105009C2 (uk) Композиції та способи, призначені для спрямованого впливу антитіл на білок с5 системи комплементу
PE20110802A1 (es) Un anticuerpo antagonista de pcsk9
PE20141151A1 (es) Proteinas de union al antigeno cd27l
AR108663A1 (es) ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ECSP066683A (es) Vacuna para mejorar el crecimiento, a base de epítopes neutralizantes
BR0111823A (pt) Polipeptìdeo, vacina, método para imunizar um animal contra um micróbio patogênico, método para identificar polipeptìdeo antigênicos, anticorpo, ou pelo menos uma parte eficaz deste, vetor, célula, método para a produção do anticorpo, linhagem celular de hibridomas, e, uso dos anticorpos.
PE20020801A1 (es) Anticuerpos contra el receptor del factor de crecimiento similar a insulina
BRPI0412245A (pt) anticorpos de rg1 e usos destes
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
MY206284A (en) Anti-cd63 antibodies, conjugates, and uses thereof
NO20063026L (no) Antistoffer
BR0211296A (pt) Peptìdeo imunogênico derivado da proteìna g do vrs do sub-grupo a ou b, sequência de ácido nucleico, composição farmacêutica, anticorpos policlonais ou monoclonais, kit de diagnóstico, utilização de um peptìdeo imunogênico, e, conjugado
RU2011142183A (ru) Средство для лечения ревматоидного артрита
PE20221865A1 (es) Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком